-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 M+QQEuH7MA3QY9s5jFd1kXJBwwGEpT79CRI2qBK0tfxanulWoGXh1+grY9iqBtnq
 aZAiNuv7zOasZTDBOc0fng==

<SEC-DOCUMENT>0001181431-10-011086.txt : 20100223
<SEC-HEADER>0001181431-10-011086.hdr.sgml : 20100223
<ACCEPTANCE-DATETIME>20100223102810
ACCESSION NUMBER:		0001181431-10-011086
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20100223
FILED AS OF DATE:		20100223
DATE AS OF CHANGE:		20100223

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			3SBio Inc.
		CENTRAL INDEX KEY:			0001383790
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33295
		FILM NUMBER:		10624617

	BUSINESS ADDRESS:	
		STREET 1:		NO.3 A1, ROAD 10 SHENYANG
		STREET 2:		ECONOMY & TECHNOLOGY DEVELOPMENT ZONE
		CITY:			SHENYANG
		STATE:			F4
		ZIP:			110027
		BUSINESS PHONE:		86-24-2581-1820

	MAIL ADDRESS:	
		STREET 1:		NO.3 A1, ROAD 10 SHENYANG
		STREET 2:		ECONOMY & TECHNOLOGY DEVELOPMENT ZONE
		CITY:			SHENYANG
		STATE:			F4
		ZIP:			110027
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>rrd267078.htm
<TEXT>

<html>
<head>
<title>Prepared By R.R. Donnelley - Form 6-K</title>
</head>
<body bgcolor="WHITE">


<hr align="left" color="#000000" noshade="noshade" size="3">

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="5"><b>SECURITIES AND EXCHANGE COMMISSION</b></font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="3"><b>Washington, DC 20549 </b></font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;">
	<font size="1"> </font>
</p>

<hr color="#000000" noshade="noshade" size="1" width="17%">

<p style="margin-top: 0px; margin-bottom: 0px;">
	<font size="1"> </font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="5"><b>FORM 6-K</b></font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;">
	<font size="1"></font>
</p>

<hr color="#000000" noshade="noshade" size="1" width="17%">

<p style="margin-top: 0px; margin-bottom: 0px;">
	<font size="1"> </font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="3"><b>REPORT OF FOREIGN PRIVATE ISSUER </b></font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="3"><b>Pursuant to Rule 13a-16 or 15d-16 of</b></font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="3"><b>the Securities Exchange Act of 1934 </b></font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;">
	<font size="1"> </font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="2"><b>February 23, 2010</b></font>
</p>

	<p style="margin-top: 0px; margin-bottom: 0px;">
		<font size="1"> </font>
	</p>



	<hr color="#000000" noshade="noshade" size="1" width="17%">

	<p style="margin-top: 0px; margin-bottom: 0px;">
		<font size="1"> </font>
	</p>

	<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
		<font face="Times New Roman" size="6"><b>3SBio Inc.</b></font>
	</p>

	<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
		<font face="Times New Roman" size="1"><b>(Translation of registrant's name into English) </b></font>
	</p>

	<p style="margin-top: 0px; margin-bottom: 0px;">
		<font size="1"> </font>
	</p>

	<hr color="#000000" noshade="noshade" size="1" width="17%">

	<p style="margin-top: 0px; margin-bottom: 0px;">
		<font size="1"> </font>
	</p>
	<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
		<font face="Times New Roman" size="2">
			<b>
				No. 3 A1, Road 10<br>Shenyang Economy & Technology Development Zone<br>Shenyang 110027<br>People's Republic of China
			</b>
		</font>
	</p>

	<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
		<font face="Times New Roman" size="1"><b>(Address of principal executive offices) 	</b></font>
	</p>

<p style="margin-top: 0px; margin-bottom: 0px;">
	<font size="1"> </font>
</p>

<hr color="#000000" noshade="noshade" size="1" width="90%">

<p style="margin-top: 0px; margin-bottom: 0px;">
	<font size="1"> </font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="2">Indicate by check mark whether the registrant files or will </font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="2">file annual reports under
cover of Form 20-F or Form 40-F. </font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;">
	<font size="1"> </font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="2">
		Form 20-F <u><b>&nbsp;&nbsp;X&nbsp;&nbsp;</b></u> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form 40-F <u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>
	</font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;">
	<font size="1">&nbsp;</font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;">
	<font face="Times New Roman" size="2">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(1):
		<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>
	</font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;">
	<font size="1"> </font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;">
	<font face="Times New Roman" size="2">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(7):
		<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>
	</font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;">
	<font size="1">&nbsp;</font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="2">Indicate by check mark whether the registrant by furnishing the </font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="2">information contained
in this form is also thereby furnishing the </font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="2">information to the Commission pursuant to Rule 12g3-2(b) under the </font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="2">Securities Exchange Act of 1934.</font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;">
	<font size="1"> </font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="2">
		Yes
		<u>&nbsp;&nbsp;&nbsp;</u>
		&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
		No
		<u><b>&nbsp;&nbsp;X&nbsp;&nbsp;</b></u>
	</font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;">
	<font size="1">&nbsp;</font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="2">If "Yes" is marked, indicate below the file number assigned to the </font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="2">registrant in connection with Rule 12g3-2(b): <u>82-</u>.
</font>
</p>

<p style="margin-top: 0px; margin-bottom: -6px;">
	<font size="1"> </font>
</p>

<hr align="left" color="#000000" noshade="noshade" size="3">

<hr align="center" color="#999999" size="3" width="100%">

<p style="margin-top: 0px; margin-bottom: -6px;">
 	<font face="Times New Roman" size="2">
 		3SBio Inc. is furnishing under the cover of Form 6-K:<p>Exhibit 99.1 Press release, dated February 11, 2010, regarding that 3SBio Inc. submits application for NuPIAO Phase I clinical trial.
	</font>
</p>

<hr align="center" color="#999999" size="3" width="100%">

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="2">SIGNATURES </font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;">
	<font size="1">&nbsp;</font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px; text-indent: 4%;">
	<font face="Times New Roman" size="2">Pursuant
	to the requirements of the Securities Exchange Act of 1934, the
	registrant has duly caused this report to be signed on its behalf by
	the
	undersigned, thereunto duly authorized. </font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;">
	<font size="1">&nbsp;</font>
</p>
<table border="0" cellpadding="0" cellspacing="0" width="100%">

			<tr>
				<td valign="top">
					<p style="margin-left: 1em; text-indent: -1em;">
						<font face="Times New Roman" size="2">

						</font>
					</p>
				</td>
				<td colspan="3" valign="top">

						<font face="Times New Roman" size="2">
							3SBio Inc.
						</font>

				</td>
			</tr>

			<tr>
				<td valign="top">

						<font face="Times New Roman" size="2">
							Date : February 23, 2010
						</font>

				</td>
				<td valign="top">

						<font face="Times New Roman" size="2">
							By:
						</font>

				</td>

				<td valign="bottom">
					<font size="1"> </font>
				</td>
				<td valign="bottom">

						<font face="Times New Roman" size="2">
							<u>/s/ Dr. Jing Lou&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>
						</font>


				</td>
			</tr>
			<tr>
				<td valign="top">

						<font face="Times New Roman" size="2">

						</font>

				</td>
				<td valign="top">

						<font face="Times New Roman" size="2">
							Name:
						</font>

				</td>
				<td valign="bottom">
					<font size="1"> </font>
				</td>
				<td valign="bottom">

						<font face="Times New Roman" size="2">
							Dr. Jing Lou
						</font>

				</td>
			</tr>
			<tr>
				<td valign="top">

						<font face="Times New Roman" size="2">
							&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
						</font>

				</td>
				<td valign="top">

						<font face="Times New Roman" size="2">
							Title:
						</font>

				</td>

				<td valign="bottom">
					<font size="1"> </font>
				</td>
				<td valign="bottom">

						<font face="Times New Roman" size="2">
							Chief Executive Officer
						</font>

				</td>
			</tr>
			<tr>
				<td>
					&nbsp;
				</td>
			</tr>


		</table>


	<p Style='page-break-before:always'>
	<hr  Size="3" Width="100%" Align="center">
		<div Align="center"><font Face="times New Roman" Size="3" Color="#000000">
	<b>Exhibit Index </b></font>
	</div>

	<div><font Size="2">&nbsp;</font></div>

	<div Align="center">
	<table Cellspacing="0" Cellpadding="0" Width="100%" Border="0">
		<tr>
			<td Valign="top" Align="left">
		<div Align="left"><font Face="times New Roman" Size="2" Color="#000000">
		<b>Exhibit&nbsp;No.</b></font>
		</div>
			<hr Size="2" Noshade Width="48" Color="#000000">
			</td>
			<td Valign="top" Width="3%"><font Face="times New Roman" Size="2">&nbsp;&nbsp;</font></td>
			<td Valign="top" Width="100%" Align="left">
		<div><font Face="times New Roman" Size="2" Color="#000000">
		<b>Description</b></font>
		</div>
		<hr Size="2" Noshade Width="73" Align="left" Color="#000000">
			</td>
		</tr>


		<tr>
			<td Valign="top" Align="left">
		<div Align="left"><font Face="times New Roman" Size="1" Color="#000000">
		EX-99.1</font>
		</div>

			</td>
			<td Valign="top" Width="3%"><font Face="times New Roman" Size="2">&nbsp;&nbsp;</font></td>
			<td Valign="top" Width="100%" Align="left">
		<div><font Face="times New Roman" Size="2" Color="#000000">
		3SBio Inc. Submits Application for NuPIAO Phase I Clinical Trial</font>
		</div>
			</td>
		</tr>
		<tr>
			<td>
				&nbsp;
			</td>
		</tr>


		</table>


<BR><BR><BR>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>rrd267078_320.htm
<DESCRIPTION>3SBIO INC. SUBMITS APPLICATION FOR NUPIAO PHASE I CLINICAL TRIAL
<TEXT>
<HTML>
<HEAD>
<TITLE>3SBio Inc</TITLE>
<META NAME="DocID_Include" CONTENT="On">
</HEAD>
<BODY LINK="#0000ff">
<B><I><P ALIGN="JUSTIFY">FOR RELEASE FEBRUARY 11, 2010 8:00 pm Eastern Time</P>
</I><P ALIGN="CENTER">3SBio Inc. Submits Application for NuPIAO Phase I Clinical Trial </P>
</B><FONT SIZE=2><P ALIGN="JUSTIFY">SHENYANG, PRC - February 11, 2010 - 3SBio Inc. (NASDAQ: SSRX), a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, today announced that it has submitted its application for a Phase I clinical trial for NuPIAO to the Chinese State Food and Drug Administration (SFDA).  NuPIAO is a highly glycosylated ESA (erythropoiesis-stimulating agent) with extended half-life and increased biologic activity.  Pre-clinical results showed a promising pharmacokinetic profile which would allow a once weekly injection schedule of NuPIAO in humans.  NuPIAO will be investigated to treat anemia associated with both chronic kidney disease and cancer.  </P>
<P ALIGN="JUSTIFY"> &quot;This submission represents another important milestone in our effort to extend our market leading EPO franchise and continue to serve the needs of patients in China,&quot; said Dr. Jing Lou, CEO of 3SBio. &quot;It is a direct result of our dedicated R&amp;D effort to generate an innovative pipeline and create long term value for shareholders.&quot;</P>
<B><P>About 3SBio Inc.</B><BR>
<BR>
3SBio Inc. is a leading, fully integrated biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, primarily in China. For more information, please visit 3SBio on the web at www.3sbio.com.</P>
<B><P>Safe Harbor Statement:</P>
</B><P>This press release contains statements of a forward-looking nature. These statements are made under the &quot;safe harbor&quot; provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by terminology such as &quot;will,&quot; &quot;expects,&quot; &quot;anticipates,&quot; &quot;future,&quot; &quot;intends,&quot; &quot;plans,&quot; &quot;believes,&quot; &quot;estimates&quot; and similar statements. The accuracy of these statements may be impacted by a number of business factors and uncertainties that could cause actual results to differ materially from those projected or anticipated, including factors related to: the ability of 3SBio to initiate and successfully complete the registrational trial for NuPIAO; the risk that 3SBio may not be able to commercially offer NuPIAO in China in a timely manner or at all for whatever reason, including possible failure to obtain SFDA approval; uncertainty as to hospital or patient demand for 3SBio's pr
oducts; uncertainties regarding 3SBio's ability to successfully compete in the ESA market in China; uncertainties regarding 3SBio's ability to obtain favorable insurance coverage and pricing for NuPIAO, if approved by the SFDA; changes in the healthcare industry in China, including changes in the healthcare policies and regulations of the P.R.C. government and changes in the healthcare insurance sector in the P.R.C.; fluctuations in general economic and business conditions in China; and other risks outlined in 3SBio's filings with the Securities and Exchange Commission. 3SBio does not undertake any obligation to update this forward-looking information, except as required under applicable law. </P>
<B><P ALIGN="JUSTIFY">Investor Contacts:</P>
</B><P>Bo Tan<BR>
Chief Financial Officer<BR>
3SBio Inc.<BR>
Tel: + 86 24 2581-1820<BR>
</FONT><FONT FACE="Calibri,Arial Narrow" SIZE=2><FONT FACE="Calibri,Arial Narrow" SIZE=2>ir@3SBio.com</P>
</FONT></FONT><FONT SIZE=2><P>Tom Folinsbee<BR>
Director of Investor Relations<BR>
3SBio Inc. <BR>
Tel: + 852 8191-6991<BR>
</FONT><FONT FACE="Calibri,Arial Narrow" SIZE=2><FONT FACE="Calibri,Arial Narrow" SIZE=2>ir@3SBio.com</P>
</FONT></FONT><FONT SIZE=2><P>&lt;END&gt;</P></FONT></BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
